nach oben

Drugs & Aging

Erschienen in:

01.05.2001 | Review Article

Selective Serotonin Reuptake Inhibitors for Late-Life Depression

A Comparative Review

verfasst von: Dr LalithKumar K. Solai, Benoit H. Mulsant, Bruce G. Pollock

Erschienen in: Drugs & Aging | Ausgabe 5/2001

Einloggen, um Zugang zu erhalten

Abstract

Late-life depression is a serious health problem that is challenging to manage but generally responds well to pharmacotherapy. Selective serotonin (5-hydroxy-tryptamine; 5-HT) reuptake inhibitors (SSRIs), the most commonly prescribed antidepressants, are usually used as first-line agents for elderly patients with depression. Like most drugs, SSRIs have not been widely tested in clinical trials that approximate ‘real-life’ geriatric situations. However, studies completed to date provide valuable information about the efficacy, safety and tolerability of this class of antidepressants among older patients with depression, including those with depression secondary to stroke or dementia and those with other comorbid physical disorders.

Although one SSRI may be more efficacious or better tolerated by elderly patients than another, existing data do not support such claims. However, other distinguishing features may influence the choice of agent. For example, fluoxetine, fluvoxamine and paroxetine are more likely to be involved in significant drug-drug interactions than are citalopram or sertraline. In contrast to the other SSRIs, fluoxetine has a half-life well in excess of 1 day, which can be an advantage when weaning the patient off therapy in that it may reduce the incidence of discontinuation symptoms, but a significant disadvantage if the patient cannot tolerate the drug or experiences an adverse drug-drug interaction.

Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. JAMA 1993; 270: 1819–25PubMedCrossRef

Rovner BW. Depression and increased risk of mortality in the nursing home patient. Am J Med 1993; 94(5A): 19S–22SPubMed

Schneider LS, Reynolds CFI, Lebowitz BD, et al., editors. Diagnosis and treatment of depression in late life, 4th ed. Washington, DC: American Psychiatric Press, Inc., 1997

Mulsant BH, Ganguli M. Epidemiology and diagnosis of depression in late-life. J Clin Psychiatry 1999; 60Suppl. 20: 9–15PubMed

Mamdani MM. Parikh SV, Austin PC, et al. Use of antidepressants among elderly subjects: trends and contributing factors. Am J Psychiatry 2000; 157(3): 360–7PubMedCrossRef

Solai LK, Mulsant BH, Pollock BG, et al. Update on the treatment of late-life depression. In: Dunner DL, Rosenbaum JF, editors. Psychiatric clinics of North America annual of drug therapy1999. Philadelphia: WB Saunders, 1999: 73–92

Kyle CJ, Petersen HE, Overo KF. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998; 8(4): 147–53PubMedCrossRef

Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994; 25(6): 1099–104PubMedCrossRef

Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. Br J Psychiatry 1990; 157: 894–901PubMedCrossRef

10.

Nyth AL, Gottfries CG, Lyby K, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psy-chiatr Scand 1992; 86(2): 138–45CrossRef

11.

Tollefson GD, Bosomworth JC, Heiligenstein JH, et al. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression: the Fluoxetine Col-laborative Study Group. Int Psychogeriatr 1995;7(1): 89–104PubMedCrossRef

12.

Altamura AC, De Novellis F, Guercetti G, et al. Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial. Int J Clin Pharmacol Res 1989; 9(6): 391–6PubMed

13.

Feighner JP, Cohn JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry 1985; 46(3): 20–5PubMed

14.

Schone W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993; 13 (6 Suppl. 2): 34S–9SPubMed

15.

Evans M, Hammond M, Wilson K, et al. Treatment of depression in the elderly: effect of physical illness on response. Int J Geriatr Psychiatry 1997; 12(12): 1189–94PubMedCrossRef

16.

Taragano FE, Lyketsos CG, Mangone CA, et al. A double-blind, randomized, fixed-dose trial of fluoxetine vs amitriptyline in the treatment of major depression complicating Alzheimer’s disease. Psychosomatics 1997; 38(3): 246–52PubMedCrossRef

17.

Trappler B, Cohen CI. Use of SSRIs in ‘very old’ depressed nursing home residents. Am J Geriatr Psychiatry 1998; 6(1): 83–9PubMed

18.

Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000; 157(3): 351–9PubMedCrossRef

19.

Finkel SI, Richter EM, Clary CM, et al. Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression. Am J Geriatr Psychiatry 1999; 7: 221–7PubMedCrossRef

20.

Nobler MS, Devanand DP, Kim MK, et al. Fluoxetine treatment of dysthymia in the elderly. J Clin Psychiatry 1996; 57: 254–6PubMed

21.

Orengo CA, Kunik ME, Molinari V, et al. The use and toler-ability of fluoxetine in geropsychiatric inpatients. J Clin Psychiatry 1996; 57: 12–6PubMed

22.

Wakelin JS. Fluvoxamine in the treatment of the older depressed patient: double-blind, placebo-controlled data. Int Clin Psy-chopharmacol 1986; 1(3): 221–30CrossRef

23.

Rahman MK, Akhtar MJ, Savla NC, et al. A double-blind, randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients. Br J Clin Pract 1991; 45(4): 255–8PubMed

24.

Phanjoo AL, Wonnacott S, Hodgson A. Double-blind comparative multicentre study of fluvoxamine and mianserin in the treatment of major depressive episode in elderly people. Acta Psychiatr Scand 1991; 83(6): 476–9PubMedCrossRef

25.

Dunner DL, Cohn JB, Walshe TD, et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 1992; 53 Suppl: 57–60PubMed

26.

Guillibert E, Pelicier Y, Archambault JC, et al. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand Suppl 1989; 350: 132–4PubMedCrossRef

27.

Geretsegger C, Stuppaeck CH, Mair M, et al. Multicenter double-blind study of paroxetine and amitriptyline in elderly depressed inpatients. Psychopharmacology (Berl)1995; 119(3): 277–81CrossRef

28.

Katona CLE, Hunter BN, Bray J. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 1998; 13: 100–8PubMedCrossRef

29.

Mulsant BH, Pollock BG, Nebes RD, et al. A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. J Clin Psychiatry 1999; 60Suppl. 20: 16–20PubMed

30.

Bondareff W, Alpert M, Friedhoff AJ, et al. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 2000; 157(5): 729–36PubMedCrossRef

31.

Newhouse PA, Krishnan KR, Doraiswamy PM, et al. A doubleblind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 2000; 61(8): 559–68PubMedCrossRef

32.

Cohn CK, Shrivastava R, Mendels J, et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990; 51Suppl B: 28–33PubMed

33.

Arranz FJ, Ros S. Effects of comorbidity and polypharmacy on the clinical usefulness of sertraline in elderly depressed patients: an open multicentre study. J Affect Disord 1997; 46(3): 285–91PubMedCrossRef

34.

Oslin DW, Streim JE, Katz IR, et al. Heuristic comparison of sertraline with nortriptyline for the treatment of depression in frail elderly patients. Am J Geriatr Psychiatry 2000; 8: 141–9PubMed

35.

Lyketsos CG, Sheppard JE, Steele CD, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer’ s disease study. Am J Psychiatry 2000; 157: 1686–9PubMedCrossRef

36.

Rosen J, Mulsant BH, Pollock BG. Sertraline in the treatment of minor depression in nursing home residents: a pilot study. Int J Geriatr Psychiatry 2000; 15(2): 177–8PubMedCrossRef

37.

Aguglia E, Casacchia M, Cassano GB, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993; 8(3): 197–202PubMedCrossRef

38.

Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 1995; 56(6): 229–37PubMed

39.

Boyer P, Danion JM, Bisserbe JC, et al. Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression: a 6-month double-blind study in a primary-care setting in France. Pharmacoeconomics 1998; 13 (1 Pt 2): 157–69PubMedCrossRef

40.

De Wilde J, Spiers R, Mertens C, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993; 87(2): 141–5PubMedCrossRef

41.

Ekselius L, von Knorring L, Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997; 12(6): 323–31PubMedCrossRef

42.

Fava M, Amsterdam JD, Deltito JA, et al. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry 1998; 10(4): 145–50PubMed

43.

Haffmans PM, Timmerman L, Hoogduin CA. Efficacy and tol-erability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group. Int Clin Psychopharmacol 1996; 11(3): 157–64PubMedCrossRef

44.

Kiev A, Feiger A. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 1997; 58(4): 146–52PubMedCrossRef

45.

Patris M, Bouchard JM, Bougerol T, et al. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996; 11(2): 129–36PubMed

46.

Rapaport M, Coccaro E, Sheline Y, et al. A comparison of flu-voxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 1996; 16(5): 373–8PubMedCrossRef

47.

Tignol J. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 1993; 13 (6 Suppl. 2): 18S–22SPubMed

48.

Zanardi R, Franchini L, Gasperini M, et al. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 1996; 153(12): 1631–3PubMed

49.

Pollock BG, Mulsant BH, Nebes RD, et al. Serum anti-cholinergicity in older patients treated with paroxetine or nor-triptyline. Am J Psychiatry 1998; 155(8): 1110–2PubMed

50.

Physicians’ Desk Reference. Montvale (NJ): Medical Economics, 1999

51.

Liu B, Anderson G, Mittman N, et al. Use of selective serotonin reuptake inhibitors or tricyclic antidepressants and risks of hip fractures in elderly people. Lancet 1998; 351(9112): 1303–7PubMedCrossRef

52.

Thapa PB, Gideon P, Cost TW, et al. Antidepressant and the risk of falls among nursing home residents. N Engl J Med 1998; 339: 875–82PubMedCrossRef

53.

Whooley MA, Kip KE, Cauley JA, et al. Depression, falls and risks of fractures in older women. Arch Intern Med 1999; 159: 484–90PubMedCrossRef

54.

Druckenbord R, Mulsant BH. Fluoxetine induced syndrome of inappropriate anti-diuretic hormone: a geriatric case report and a review of literature. J Geriatr Psychol Neurol 1994; 7(4): 254–6

55.

Woo MH, Smythe MA. Association of SIADH with selective serotonin reuptake inhibitors. Ann Pharmacother 1997; 31: 108–10PubMed

56.

Andersen G, Bayer H, Flicker C. A placebo-controlled study of citalopram treatment for post-stroke depression. Presented at the American Association of Geriatric Psychiatry meeting; 1998 Mar 10, San Diego (CA)

57.

Jeppesen U, Gram L, Vistisen K. Dose-dependent inhibition of CYP1A2, CYP2C19, and CYP2D6 by citalopram, fluoxetine, fluvoxamine, and paroxetine. Eur J Clin Pharmacol 1996; 51: 73–8PubMedCrossRef

58.

Otton SV, Wu D, Joffe RT, et al. Inhibitions by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53: 401–9PubMedCrossRef

59.

Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34(3): 262–5PubMedCrossRef

60.

Belpaire FM, Wijnant P, Temmerman A, et al. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol 1998; 54(3): 261–4PubMedCrossRef

61.

von Moltke LL, Greenblatt DJ, Court MH, et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psycho-pharmacol 1995; 15(2): 125–31CrossRef

62.

Iribarne C, Picart D, Dreano Y, et al. In vitro interactions between fluoxetine or fluvoxamine and methadone or bupren-orphine. Fundam Clin Pharmacol 1998; 12(2): 194–9PubMedCrossRef

63.

Rasmussen BB, Nielsen TL, Brosen K. Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol 1998; 83(6): 240–5PubMedCrossRef

64.

Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of flu-voxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther 1998; 64(3): 257–68PubMedCrossRef

65.

Brøsen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45(6): 1211–4PubMedCrossRef

66.

Schmider J, Greenblatt DJ, von Moltke LL, et al. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br J Clin Pharmacol 1997; 44(5): 495–8PubMedCrossRef

67.

Syvalahti EKG, Taiminen T, Saarijarvi S, et al. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res 1997; 25(1): 24–32PubMed

68.

Gram LF, Hansen MG, Sindrup SH, et al. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 1993; 15(1): 18–24PubMedCrossRef

69.

Kobayashi K, Yamamoto T, Chiba K, et al. The effects of selec-tive serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4’-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995; 40(5): 481–5PubMedCrossRef

70.

van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993; 24(3): 203–20PubMedCrossRef

71.

Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44(2): 77–87PubMedCrossRef

72.

Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 288–95PubMedCrossRef

73.

Overø KF. Kinetics of citalopram in man: plasma levels in patients. Neuropsychopharmacol Biol Psychiatry 1982; 6: 311–8CrossRef

74.

Fredricson Overø K, Toft B, Christophersen L, et al. Kinetics of citalopram in elderly patients. Psychopharmacology 1985; 86(3): 253–7CrossRef

75.

Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997; 32Suppl. 1: 22–30PubMedCrossRef

Titel: Selective Serotonin Reuptake Inhibitors for Late-Life Depression
A Comparative Review
verfasst von: Dr LalithKumar K. Solai
Benoit H. Mulsant
Bruce G. Pollock
Publikationsdatum: 01.05.2001
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 5/2001
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200118050-00006

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2001

Treatment of Systemic Fungal Infections in Older Patients

Medical Management of Patients with Refractory Carcinoma In Situ of the Bladder

Indobufen

Optimisation of the Management of Patients with Coronary Heart Disease and Type 2 Diabetes Mellitus

Improved Outcomes with Antihypertensive Medication in the Elderly with Isolated Systolic Hypertension